Research on how soon people respond to a GLP-1 asks when differences show up. This analysis used records from 135,349 people treated with semaglutide or tirzepatide to describe the spread in outcomes [1]. It identified people who lost more than 15%, those who lost 5% to 15%, those with minimal weight loss, and those who gained more than 5%.
Within the four named brand groups, 40% to 42% of patients lost 5% to 15% of their starting weight. The share losing more than 15% varied more widely: 34% on Zepbound, 26% on Wegovy, 24% on Mounjaro and 10% on Ozempic [1].
The STEP trials report outcomes for the same semaglutide dose in different populations. In STEP 1, adults without diabetes on semaglutide 2.4 mg lost a mean 14.9% of body weight over 68 weeks, and 50.5% of them lost 15% or more [2]. In STEP 2, the same 2.4 mg dose in adults with type 2 diabetes produced a mean loss of 9.6% over 68 weeks [3]. At 72 weeks, the tirzepatide 15 mg group lost a mean 20.9% in SURMOUNT-1, which excluded diabetes [4]. In SURMOUNT-2, which enrolled people with type 2 diabetes, the same dose produced a mean loss of 14.7% [5].
These trials enrolled different populations. The comparisons cannot isolate the effect of diabetes status. STEP 1 counted participants who lost at least 15%, while the records study used a threshold above 15%. The studies also differed in how treatment and weight were tracked.
Compared with the moderate and minimal weight-loss groups, the largest responders were younger and more often women. Compared with the minimal weight-loss group, they were also more often White [1]. Our guide to patient characteristics in weight-loss research explains why differences in who receives treatment matter when interpreting observed outcomes. The study did not establish what caused these differences.
The paper’s results section reports that fibromyalgia and osteoarthritis were less common before treatment among the largest Zepbound responders than among matched patients with minimal weight loss. The abstract describes the conditions as more common, which conflicts with the direction reported in the results [1]. These associations describe the study groups and do not predict an individual response.
The study grouped patients by the weight change recorded in their health records. Its observational design leaves room for differences in the patients prescribed each brand and in how they used it. Our review of treatment persistence explains how refill gaps and discontinuation can affect real-world comparisons. These brand-level results cannot predict how much weight an individual will lose.